Order Article Reprints

Provez L, Putteman T, Landfors M, Roels J, Reunes L, T’Sas S, Van Loocke W, Lintermans B, De Coninck S, Thenoz M, et al. Pre-Clinical Evaluation of the Hypomethylating Agent Decitabine for the Treatment of T-Cell Lymphoblastic Lymphoma. Cancers. 2023; 15(3):647. https://doi.org/10.3390/cancers15030647

Provez, Lien, Tom Putteman, Mattias Landfors, Juliette Roels, Lindy Reunes, Sara T’Sas, Wouter Van Loocke, Béatrice Lintermans, Stien De Coninck, Morgan Thenoz, and et al. 2023. "Pre-Clinical Evaluation of the Hypomethylating Agent Decitabine for the Treatment of T-Cell Lymphoblastic Lymphoma" Cancers 15, no. 3: 647. https://doi.org/10.3390/cancers15030647

Provez, L., Putteman, T., Landfors, M., Roels, J., Reunes, L., T’Sas, S., Van Loocke, W., Lintermans, B., De Coninck, S., Thenoz, M., Sleeckx, W., Maćkowska-Maślak, N., Taghon, T., Mansour, M. R., Farah, N., Norga, K., Vandenberghe, P., Kotecha, R. S., Goossens, S., ... Van Vlierberghe, P. (2023). Pre-Clinical Evaluation of the Hypomethylating Agent Decitabine for the Treatment of T-Cell Lymphoblastic Lymphoma. Cancers, 15(3), 647. https://doi.org/10.3390/cancers15030647